{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T16:29:05Z","timestamp":1788020945562,"version":"build-2784847793"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Drug supply shortages are a recurring issue in developed countries, with consequences for patients even before the COVID-19 pandemic. Questions arise regarding the effectiveness and tolerability of alternative treatments chosen by physicians due to these shortages.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>To answer these questions, a survey for practicing physicians was distributed to medical associations in Germany and Austria and conducted from November 2022 to January 2024. 895 physicians responded to the survey. The survey targeted 20 drugs with known supply shortages, namely amoxicillin, amoxicillin\/clavulanic acid, penicillin V (phenoxymethylpenicillin), cefuroxime, cefaclor, erythromycin, cotrimoxazole, ibuprofen, paracetamol, urapidil, metoprolol, amlodipine, candesartan, tamoxifen, methotrexate, fluoxetine, lorazepam, human insulin, salbutamol and prednisolone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Physicians most frequently chose a different antibacterial drug (&gt;\u200960% of the physicians), while for analgesics, they more often used a different dosage form of the same drug (&gt;\u200933%). For antihypertensive drugs, physicians more often chose a different dosage of the same drug. In many cases, alternative antibiotics were chosen that carried a greater risk of antimicrobial resistance than the antibiotic originally intended. The treatment success for replacing antibacterials and analgesics with a different drug was rated with 4\u20135 on a predefined scale of 1 (very poor) to 6 (very good) in comparison to the original drug. Using the same drug in a different dosage\/dosage form was also around 4\u20135\/6 effective.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Supply shortages can foster antimicrobial resistance through the use of antibacterials with a higher potential for resistance. The success of alternative treatments was not always considered to be very good in comparison to the original medication.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00228-026-04052-4","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T02:10:26Z","timestamp":1777601426000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Drug supply shortages and their perceived consequences for patients: a questionnaire survey of German and Austrian physicians"],"prefix":"10.1007","volume":"82","author":[{"given":"Julia Maria","family":"Rotter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"key":"4052_CR1","unstructured":"Kassen\u00e4rztliche Vereinigung Berlin (2023) Auswertung Umfrage Medikamentenengp\u00e4sse Erfahrung und Einsch\u00e4tzung der Berliner Praxen. https:\/\/www.kvberlin.de\/fileadmin\/user_upload\/die_kvberlin\/presse\/2023-08-23_Mitgliederumfrage_Praxen_medikamentenmangel.pdf. Accessed 6 Jan 2025"},{"key":"4052_CR2","unstructured":"PHAGRO Bundesverband des pharmazeutischen Gro\u00dfhandels e.V (2024) Arzneimittel-Lieferengp\u00e4sse: Alltag in Deutschland. https:\/\/www.phagro.de\/app\/uploads\/2024\/12\/Phagro-Umfrage-Forsa-2024.pdf."},{"key":"4052_CR3","unstructured":"Bundesvereinigung Deutscher Apothekerverb\u00e4nde (ABDA) (2023) \u00d6sterreich: Rund jeder Sechste ist von Lieferengp\u00e4ssen betroffen. https:\/\/www.abda.de\/aktuelles-und-presse\/newsroom\/detail\/oesterreich-rund-jeder-sechste-ist-von-lieferengpaessen-betroffen\/. Accessed 12 Jan 2025"},{"key":"4052_CR4","unstructured":"World Health Organisation (WHO) (2023) WHO model list of essential medicines \u2013 23rd list. https:\/\/iris.who.int\/bitstream\/handle\/10665\/371090\/WHO-MHP-HPS-EML-2023.02-eng.pdf?sequence=1. Accessed 28 Jan 2025"},{"key":"4052_CR5","unstructured":"European Medicines Agency, Heads of Medicines Agencies, European Commission (2023) Union list of critical medicines -version 1. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/post-authorisation\/medicine-shortages-availability-issues\/availability-medicines-during-crises\/union-list-critical-medicines. Accessed 28 Jan 2025"},{"key":"4052_CR6","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (BfArM) (2024) Ver\u00f6ffentlichte Lieferengpassmeldungen. https:\/\/anwendungen.pharmnet-bund.de\/lieferengpassmeldungen\/faces\/public\/meldungen.xhtml?jfwid=A2BA4CD661DC3A261971A9A307C5EAED%3A1. Accessed 12 Jan 2025"},{"key":"4052_CR7","unstructured":"Gelbe Liste (2023) Lieferengp\u00e4sse bei Medikamenten. www.gelbe-liste.de. Accessed 5 Nov 2023"},{"key":"4052_CR8","unstructured":"Rote Liste (2025) Rote Liste Arzneimittelinformationen f\u00fcr Deutschland. www.rote-liste.de. Accessed 21 Mar 2025"},{"key":"4052_CR9","unstructured":"Leiner D (2024) SoSci der Online Fragebogen. https:\/\/www.soscisurvey.de\/. Accessed 15 Feb 2026"},{"key":"4052_CR10","unstructured":"Daniel D (2025) \u00c4rztestatistik: Das sind die 15 gr\u00f6\u00dften Facharztgruppen. In: \u00c4RZTESTELLEN Der Stellenmarkt des Deutschen \u00c4rzteblattes. https:\/\/aerztestellen.aerzteblatt.de\/de\/redaktion\/aerztestatistik-das-sind-die-15-groessten-facharztgruppen. Accessed 15 Feb 2026"},{"key":"4052_CR11","doi-asserted-by":"crossref","unstructured":"World Health Organization (WHO) (2025) The selection and use of essential medicines, 2025: WHO AWaRe (Access, Watch, Reserve) classification of antibiotics for evaluation and monitoring of use. https:\/\/www.who.int\/publications\/i\/item\/B09489. Accessed 12 Mar 2026","DOI":"10.2471\/B09489"},{"key":"4052_CR12","doi-asserted-by":"publisher","unstructured":"Moja L, Zanichelli V, Mertz D, Gandra S, Cappello B, Cooke GS, Chuki P, Harbarth S, Pulcini C, Mendelson M, Tacconelli E, Ombajo LA, Chitatanga R, Zeng M, Imi M, Elias C, Ashorn P, Marata A, Paulin S et al (2024) WHO\u2019s essential medicines and AWaRe: recommendations on first- and second-choice antibiotics for empiric treatment of clinical infections. Clin Microbiol Infect. https:\/\/doi.org\/10.1016\/j.cmi.2024.02.003","DOI":"10.1016\/j.cmi.2024.02.003"},{"key":"4052_CR13","doi-asserted-by":"publisher","unstructured":"Russell AM, Opsasnick L, Weiner-Light S, Bailey SC, O\u2019Brien M, Wolf MS (2023) Medication dosing schedules, medication knowledge, and dosing errors of adults taking complex drug regimens. J Health Care Poor Underserved. https:\/\/doi.org\/10.1353\/hpu.2023.0013","DOI":"10.1353\/hpu.2023.0013"},{"key":"4052_CR14","doi-asserted-by":"publisher","unstructured":"Vallet T, Bensouda Y, Saito J, Mathiesen L, Pokharkar V, Klingmann V, Peak M, Elhamdaoui O, Yamatani A, Ivanovic I, Sajith M, M\u00fcnch J, Bracken L, Duncan JC, Salunke S, Wang S, Ruiz F (2021) Exploring acceptability drivers of oral antibiotics in children: findings from an international observational study. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics13101721","DOI":"10.3390\/pharmaceutics13101721"},{"key":"4052_CR15","doi-asserted-by":"publisher","unstructured":"Legha SS (1988) Tamoxifen in the treatment of breast cancer. Ann Intern Med. https:\/\/doi.org\/10.7326\/0003-4819-109-3-219","DOI":"10.7326\/0003-4819-109-3-219"},{"key":"4052_CR16","doi-asserted-by":"publisher","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (1988) Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJM198812293192601","DOI":"10.1056\/NEJM198812293192601"},{"key":"4052_CR17","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (2022) Tamoxifen aktuelle Empfehlungen. https:\/\/www.dggg.de\/fileadmin\/data\/Stellungnahmen\/DGGG\/2022\/Empfehlungen_zum_Lieferengpass_Tamoxifen_09.02.2022_01.pdf. Accessed 16 Oct 2025"},{"key":"4052_CR18","doi-asserted-by":"publisher","unstructured":"Becker DJ, Talwar S, Levy BP, Thorn M, Roitman J, Blum RH, Harrison LB, Grossbard ML (2013) Impact of oncology drug shortages on patient therapy: unplanned treatment changes. J Oncol Pract. https:\/\/doi.org\/10.1200\/JOP.2012.000799","DOI":"10.1200\/JOP.2012.000799"},{"key":"4052_CR19","doi-asserted-by":"publisher","unstructured":"GBD (2021) Antimicrobial Resistance Collaborators (2024) Global burden of bacterial antimicrobial resistance 1990\u20132021: a systematic analysis with forecasts to 2050. Lancet. https:\/\/doi.org\/10.1016\/S0140-6736(24)01867-1","DOI":"10.1016\/S0140-6736(24)01867-1"},{"key":"4052_CR20","unstructured":"Bundesministerium f\u00fcr Gesundheit (2026) DART 2030 - Deutsche Antibiotika-Resistenzstrategie. https:\/\/www.bundesgesundheitsministerium.de\/themen\/praevention\/antibiotika-resistenzen\/dart-2030. Accessed 17 Mar 2026"},{"key":"4052_CR21","unstructured":"Robert Koch Institut (RKI) (2025) Welt-Antibiotikawoche 2025: Aktuelle Trends zu Antibiotikaresistenz und -verbrauch in Deutschland. https:\/\/www.rki.de\/DE\/Themen\/Infektionskrankheiten\/Antibiotikaresistenz\/waaw-2025.html. Accessed 17 Mar 2026"},{"key":"4052_CR22","doi-asserted-by":"publisher","unstructured":"Patel H, Calip GS, DiDomenico RJ, Schumock GT, Suda KJ, Lee TA (2020) Comparison of cardiac events associated with azithromycin vs amoxicillin. JAMA Netw Open. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.16864","DOI":"10.1001\/jamanetworkopen.2020.16864"},{"key":"4052_CR23","doi-asserted-by":"publisher","unstructured":"Lee EY, Gomes T, Drucker AM, Daneman N, Asaf A, Wu F, Piguet V, Juurlink DN (2024) Oral antibiotics and risk of serious cutaneous adverse drug reactions. JAMA. https:\/\/doi.org\/10.1001\/jama.2024.11437","DOI":"10.1001\/jama.2024.11437"},{"key":"4052_CR24","doi-asserted-by":"publisher","unstructured":"Rhedin S, Kvist B, Caffrey Osvald E, Karte G, Smew AI, Naucl\u00e9r P, Lundholm C, Almqvist C (2024) Penicillin V versus amoxicillin for pneumonia in children\u2014a swedish nationwide emulated target trial. Clin Microbiol Infect. https:\/\/doi.org\/10.1016\/j.cmi.2024.06.008","DOI":"10.1016\/j.cmi.2024.06.008"},{"key":"4052_CR25","unstructured":"MSD Manual Ausgabe f\u00fcr medizinische Fachkreise (2024) Bakterien und antibakterielle Wirkstoffe. https:\/\/www.msdmanuals.com\/de\/profi\/infektionskrankheiten\/bakterien-und-antibakterielle-wirkstoffe\/%C3%BCberblick-%C3%BCber-die-antibakterielle-substanzen?_gl=1*1s9aypg*_up*MQ.*_ga*OTYxNTY4NDg0LjE3NzM1ODI0MDk.*_ga_CJ792HFYYC*czE3NzM1ODI0MDgkbzEkZzAkdDE3NzM1OTc4OTIkajYwJGwwJGgw. Accessed 15 Mar 2026"},{"key":"4052_CR26","doi-asserted-by":"crossref","unstructured":"Freissmuth M, Offermanns S, B\u00f6hm S (2024) Pharmakologie und Toxikologie Von den molekularen Grundlagen zur Pharmakotherapie, 4.Auflage. Springer Verlag GmbH, Wien und Bad Nauheim\/Frankfurt am Main","DOI":"10.1007\/978-3-662-68470-2"},{"key":"4052_CR27","unstructured":"Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e. V. (AWMF) (2023) Nationale Versorgungsleitlinie Hypertonie Langfassung. https:\/\/register.awmf.org\/assets\/guidelines\/nvl-009l_S3_Hypertonie_2023-06.pdf."},{"key":"4052_CR28","volume-title":"Mutschler Arzneimittelwirkungen","author":"G Geisslinger","year":"2020","unstructured":"Geisslinger G, Menzel S, Gudermann T, Hinz B, Ruth P (2020) Mutschler Arzneimittelwirkungen, 11. Auflage edn. Wissenschaftliche Verlagsgesellschaft Stuttgart, Frankfurt am Main, Rostock","edition":"11. Auflage"},{"key":"4052_CR29","doi-asserted-by":"crossref","unstructured":"Herdegen T, B\u00f6hm Ruwen, Culman J, Gohlke P, Luippold G, W\u00e4tzig V (2024) Kurzlehrbuch Pharmakologie und Toxikologie, 5.Auflage. Thieme, Kiel","DOI":"10.1055\/b000000849"},{"key":"4052_CR30","doi-asserted-by":"crossref","unstructured":"M\u00f6ller H, Laux G, Deister A (2015) Duale Reihe Psychiatrie, Psychosomatik und Psychotherapie, 6. Auflage. Thieme, M\u00fcnchen, Haag i. OB, Itzehoe","DOI":"10.1055\/b-003-120842"},{"key":"4052_CR31","unstructured":"Deutsches \u00c4rzteblatt (2023) Lieferengpass bei einzigem Antidepressivum f\u00fcr Kinder und Jugendliche. https:\/\/www.aerzteblatt.de\/news\/lieferengpass-bei-einzigem-antidepressivum-fuer-kinder-und-jugendliche-20468c65-f643-47bc-8d6b-9eb0450f8cd0. Accessed 21 Apr 2025"},{"key":"4052_CR32","unstructured":"Kruse J, Langewitz W, Schneider A, S\u00f6llner W, Waller C, Weidner K, Zipfel S (2025) Uexk\u00fcll Psychosomatische Medizin Theoretische Modelle und klinische Praxis, 9.Auflage. Elsevier Urban und Fischer, Marburg\/Gie\u00dfen, Basel, M\u00fcnchen, N\u00fcrnberg, N\u00fcrnberg, Dresden, T\u00fcbingen"},{"key":"4052_CR33","unstructured":"Wellh\u00f6ner H (2019) Pharmakologie und Toxikologie, 8.Auflage. Harms Verlag, Hannover"},{"key":"4052_CR34","unstructured":"Aktories K, F\u00f6rstermann U, Hofmann FB, Starke K (2017) Allgemeine und spezielle Pharmakologie und Toxikologie12. Auflage. Urban & Fischer, Freiburg im Breisgau, Mainz, M\u00fcnchen"},{"key":"4052_CR35","unstructured":"AOK (, Allgemeine Ortskrankenkasse) (2026) Priscus-Liste: potenziell ungeeignete Arzneimittel f\u00fcr \u00e4ltere Menschen. https:\/\/www.aok.de\/gp\/arzneimittel\/priscus-liste. Accessed 18 Mar 2026"},{"key":"4052_CR36","unstructured":"PRISCUS Forschungsbund (2023) PRISCUS 2.0. https:\/\/www.priscus2-0.de\/fileadmin\/media\/PRISCUS_2\/PRISCUS%202_Liste_Anhang_in_DE_nicht_verfuegbare.pdf. Accessed 13 Mar 2026"},{"key":"4052_CR37","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (BfArM) (2025) Arzneimittel-Informationssystem Datenbank AMIce. https:\/\/portal.dimdi.de\/amguifree\/termsofuse.xhtml. Accessed 27 Jun 2025"},{"key":"4052_CR38","doi-asserted-by":"publisher","unstructured":"Greenblatt DJ, Divoll M, Harmatz JS, Shader RI (1982) Pharmacokinetic comparison of sublingual lorazepam with intravenous, intra muscular, and oral lorazepam. J Pharm Sci. https:\/\/doi.org\/10.1002\/jps.2600710227","DOI":"10.1002\/jps.2600710227"},{"key":"4052_CR39","unstructured":"EAHP European Association of Hospital Pharmacists (2023) EAHP 2023 shortage survey report shortages of medicines and devices in the hospital sector- prevalence, nature and impact on patient care. https:\/\/eahp.eu\/wp-content\/uploads\/2024\/03\/shortages_survey_report_final.pdf. Accessed 15 Nov 2025"},{"key":"4052_CR40","doi-asserted-by":"publisher","unstructured":"Phuong JM, Penm J, Chaar B, Oldfield LD, Moles R (2019) The impacts of medication shortages on patient outcomes: a scoping review. PLoS One. https:\/\/doi.org\/10.1371\/journal.pone.0215837","DOI":"10.1371\/journal.pone.0215837"},{"key":"4052_CR41","doi-asserted-by":"publisher","unstructured":"Fox ER, McLaughlin MM (2018) ASHP guidelines on managing drug product shortages. Am J Health-Syst Pharm. https:\/\/doi.org\/10.2146\/ajhp180441","DOI":"10.2146\/ajhp180441"},{"key":"4052_CR42","doi-asserted-by":"publisher","unstructured":"Wittich CM, Burkle CM, Lanier WL (2014) Medication errors: an overview for clinicians. Mayo Clin Proc. https:\/\/doi.org\/10.1016\/j.mayocp.2014.05.007","DOI":"10.1016\/j.mayocp.2014.05.007"},{"key":"4052_CR43","doi-asserted-by":"publisher","unstructured":"McLaughlin M, Kotis D, Thomson K, Harrison M, Fennessy G, Postelnick M, Scheetz MH (2013) Effects on patient care caused by drug shortages: a survey. J Manag Care Pharm. https:\/\/doi.org\/10.18553\/jmcp.2013.19.9.783","DOI":"10.18553\/jmcp.2013.19.9.783"},{"key":"4052_CR44","unstructured":"EAHP European Association of Hospital Pharmacists (2018) EAHP\u2019s 2018 survey on medicines shortages to improve patient outcomes. https:\/\/eahp.eu\/wp-content\/uploads\/2024\/08\/report_medicines_shortages2018.pdf\/. Accessed 15 Nov 2025"},{"key":"4052_CR45","unstructured":"ASPE Report to Congress: Impact of Drug Shortages on Consumer Costs (2023) Office of the Assistant Secretary for Planning and Evaluation (ASPE), Washington (DC). https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK603205\/. Accessed 7 Nov 2025"},{"key":"4052_CR46","doi-asserted-by":"publisher","unstructured":"Dave CV, Pawar A, Fox ER, Brill G, Kesselheim AS (2018) Predictors of drug shortages and association with generic drug prices: a retrospective cohort study. Value Health. https:\/\/doi.org\/10.1016\/j.jval.2018.04.1826","DOI":"10.1016\/j.jval.2018.04.1826"},{"key":"4052_CR47","doi-asserted-by":"publisher","unstructured":"Hu S, Zhang J, Li J, Zhang J, Pan M, Xiang C, Dave CV, Yang C, Fang Y (2023) The impact of drug shortages on drug prices: evidence from China. Front Public Health. https:\/\/doi.org\/10.3389\/fpubh.2023.1185356","DOI":"10.3389\/fpubh.2023.1185356"},{"key":"4052_CR48","doi-asserted-by":"publisher","unstructured":"Pauwels K, Simoens S, Casteels M, Huys I (2015) Insights into European drug shortages: a survey of hospital pharmacists. PLoS One. https:\/\/doi.org\/10.1371\/journal.pone.0119322","DOI":"10.1371\/journal.pone.0119322"},{"key":"4052_CR49","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (BfArM) (2023) Task Force zur Sicherstellung der medikament\u00f6sen Versorgungin der Intensivmedizin (ICU-Wirkstofflisten). https:\/\/www.bfarm.de\/DE\/Arzneimittel\/Arzneimittelinformationen\/Lieferengpaesse\/Archiv\/Task-Force-Intensivmedizin\/_node.html. Accessed 10.11.2025"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04052-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04052-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04052-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T01:46:35Z","timestamp":1778550395000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04052-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["4052"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04052-4","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"27 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was conducted according to the guidelines of good scientific practice of the Hanover Medical School (\n                      \n                      ) and officially registered as doctoral thesis project for Julia Maria Rotter. The Hanover Medical School follows the guidelines of the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG). No personal data was collected in the survey, as no conclusions can be drawn about a specific person by giving information on the federal state in which the physician works, the specialization and the work setting. The ethics committee of the Hanover Medical School was contacted. They confirmed that anonymous surveys are not subject to consultation, as no personal data is processed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable, because the survey to collect the data was anonymous. Consequently, it is not possible to draw conclusions about individuals to ask about consent to publish.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"138"}}